Ładowanie...

Advertisement

Hoth Therapeutics Partners Altasciences For Manufacturing HT-TBI For Traumatic Brain Injury/Stroke

RTTNews | 1149 dni temu

Hoth Therapeutics Partners Altasciences For Manufacturing HT-TBI For Traumatic Brain Injury/Stroke

(RTTNews) - Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Tuesday that it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation.

HT-TBI is being developed as a novel, point-of-care therapy for the treatment and/or prevention of secondary brain injury resulting from ischemic stroke and traumatic brain injury (TBI).

HT-TBI will be developed as a ready-to-use drug-device combination product for use in non-healthcare settings by patients and caregivers at risk for stroke/TBI, emergency healthcare professionals, and military personnel.

The HT-TBI formulation development and manufacturing work by Altasciences will be used to support a future Investigational New Drug (IND) Application to initiate clinical trials.

For More Such Health News, visit rttnews.com

Tagi: HOTH

read more

Hoth Therapeutics Partners Altasciences For Study On HT-KIT Cancer Treatment

Hoth Therapeutics Partners Altasciences For Study On HT-KIT Cancer Treatment

Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday that it has completed bioanalytical method development under its prior agreement with Altasciences.

RTTNews | 625 dni temu

Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA

Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA

Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday it has submitted a request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM), a rare aggressive form of cancer.

RTTNews | 793 dni temu

Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders

Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders

Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.

RTTNews | 1049 dni temu

Sensex, Nifty Surge On Trade Deal Hopes; IT Stocks Lead Gains

Sensex, Nifty Surge On Trade Deal Hopes; IT Stocks Lead Gains

Indian shares rose notably on Wednesday, with U.S. shutdown resolution and growing optimism over a potential trade deal with the United States boosting sentiment.

RTTNews | 1g 36 minut temu

Yen Falls After Japan PM Takaichi Comments

Yen Falls After Japan PM Takaichi Comments

The Japanese yen weakened against other major currencies in the Asian session on Wednesday, as Japan's Prime Minister Sanae Takaichi signals a looser fiscal target and calls for caution in the Bank of Japan (BoJ) rate hike.

RTTNews | 2g 37 minut temu

European Shares Climb On Hopes Of US Shutdown Ending

European Shares Climb On Hopes Of US Shutdown Ending

European stocks hit a new record peak on Wednesday as an effort to end the longest-ever U.S. government shutdown headed to a final vote in the House of Representatives.

RTTNews | 2g 38 minut temu

Asian Shares Mixed As Tech Stocks Drag

Asian Shares Mixed As Tech Stocks Drag

Asian stocks ended mixed on Wednesday as concerns persisted about a potential Artificial Intelligence (AI)-driven market bubble and new data added to signs of a weakening U.S. labor market.

RTTNews | 3g 15 minut temu

Yen Falls Against Majors

Yen Falls Against Majors

The Japanese yen weakened against other major currencies in the Asian session on Wednesday.

RTTNews | 4g 40 minut temu

Warunki | Prywatność | Mapa serwisu | Site Map Calendar

© 2025 Myfxbook Ltd. Wszelkie Prawa Zastrzeżone.

Ostrzeżenie o wysokim ryzyku: handel walutami obcymi wiąże się z wysokim poziomem ryzyka, który może nie być odpowiedni dla wszystkich inwestorów. Dźwignia stwarza dodatkowe ryzyko i ryzyko straty. Zanim zdecydujesz się na handel walutami, dokładnie przemyśl swoje cele inwestycyjne, poziom doświadczenia i tolerancję ryzyka. Możesz stracić część lub całość początkowej inwestycji. Nie inwestuj pieniędzy, których nie możesz stracić. Zbadaj ryzyko związane z handlem walutami i zasięgnij porady niezależnego doradcy finansowego lub podatkowego, jeśli masz jakiekolwiek pytania. Wszelkie dane i informacje są dostarczane "tak, jak są" wyłącznie w celach informacyjnych i nie są przeznaczone do celów handlowych ani konsultacji. Wcześniejsze wyniki nie są wskaźnikiem przyszłych wyników.